AR100310A1 - MOLECULES FOR TRANSPORTATION OF IMPROVED MODULAR ANTIGEN AND ITS USES - Google Patents

MOLECULES FOR TRANSPORTATION OF IMPROVED MODULAR ANTIGEN AND ITS USES

Info

Publication number
AR100310A1
AR100310A1 ARP150100974A ARP150100974A AR100310A1 AR 100310 A1 AR100310 A1 AR 100310A1 AR P150100974 A ARP150100974 A AR P150100974A AR P150100974 A ARP150100974 A AR P150100974A AR 100310 A1 AR100310 A1 AR 100310A1
Authority
AR
Argentina
Prior art keywords
molecules
imat
module
transportation
prevention
Prior art date
Application number
ARP150100974A
Other languages
Spanish (es)
Inventor
Tammen Harald
Birte Reiche Dania
Rose Horst
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of AR100310A1 publication Critical patent/AR100310A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Insects & Arthropods (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Botany (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Proteínas recombinantes (aisladas), también denominadas como moléculas MAT mejores (iMAT), que comprende al menos un módulo de translocación, al menos un módulo de direccionamiento y al menos un módulo del antígeno, donde al menos un residuo de cisteína se sustituye con un residuo de aminoácido diferente. Tales moléculas iMAT son útiles específicamente como vacunas, por ejemplo, para terapia y/o prevención de alergias y/o enfermedades infecciosas y/o prevención de transmisión de enfermedades infecciosas en equinos. También ácidos nucleicos que codifican tales moléculas de iMAT, correspondientes vectores y células o líneas celulares primarias. Reivindicación 12: La molécula iMAT de acuerdo con cualquiera de las reivindicaciones 1 a 11, caracterizada porque comprende, con preferencia consiste en, una o más de las secuencias de aminoácidos de acuerdo con las SEQ ID Nº 7, 8, 9, 10, 11, 12, 13, 14, 17, 20, 21, 22, 23.Recombinant (isolated) proteins, also referred to as better MAT molecules (iMAT), comprising at least one translocation module, at least one addressing module and at least one antigen module, where at least one cysteine residue is replaced with a different amino acid residue. Such iMAT molecules are specifically useful as vaccines, for example, for therapy and / or prevention of allergies and / or infectious diseases and / or prevention of transmission of infectious diseases in horses. Also nucleic acids encoding such iMAT molecules, corresponding vectors and primary cells or cell lines. Claim 12: The iMAT molecule according to any one of claims 1 to 11, characterized in that it preferably comprises one or more of the amino acid sequences according to SEQ ID No. 7, 8, 9, 10, 11 , 12, 13, 14, 17, 20, 21, 22, 23.

ARP150100974A 2014-03-31 2015-03-31 MOLECULES FOR TRANSPORTATION OF IMPROVED MODULAR ANTIGEN AND ITS USES AR100310A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14162575 2014-03-31

Publications (1)

Publication Number Publication Date
AR100310A1 true AR100310A1 (en) 2016-09-28

Family

ID=50433975

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150100974A AR100310A1 (en) 2014-03-31 2015-03-31 MOLECULES FOR TRANSPORTATION OF IMPROVED MODULAR ANTIGEN AND ITS USES

Country Status (12)

Country Link
US (2) US9920101B2 (en)
EP (1) EP3125933B1 (en)
JP (1) JP6370398B2 (en)
KR (1) KR20160138283A (en)
CN (1) CN106132996B (en)
AR (1) AR100310A1 (en)
AU (1) AU2015239770B2 (en)
CA (1) CA2943690A1 (en)
EA (1) EA034692B1 (en)
MX (1) MX2016012840A (en)
TW (1) TWI705823B (en)
WO (1) WO2015150243A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160138283A (en) 2014-03-31 2016-12-02 베링거잉겔하임베트메디카게엠베하 Improved modular antigen transportation molecules and uses therof
MX2018003850A (en) 2015-09-30 2018-06-15 Boehringer Ingelheim Vetmedica Gmbh Improved modular antigen transportation molecules and uses therof in animals.
CA3080253A1 (en) 2017-10-25 2019-05-02 Allero Therapeutics Bv Treatment of immune diseases by administration of antigen-specific formulations
JP7441534B2 (en) * 2019-01-09 2024-03-01 エムディー ヘルスケア インコーポレイテッド Nanovesicles derived from Rhodococcus bacteria and their uses
CN110343160A (en) * 2019-07-26 2019-10-18 四川农业大学 Yellow meal worm YM47 albumen, its encoding gene and application
KR200494146Y1 (en) 2019-10-29 2021-08-12 김용호 Custom type functional pillow
KR200491545Y1 (en) 2019-10-29 2020-04-24 김용호 Custom type functional pillow

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5633234A (en) 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
AU6252294A (en) 1993-02-26 1994-09-14 Immtech International, Inc. A mutant protein and methods and materials for making and using it
GB9825421D0 (en) 1998-11-19 1999-01-13 Isis Innovation Process for oxidising terpenes
JP3993035B2 (en) 2001-07-19 2007-10-17 松下電器産業株式会社 Data recording method, recording medium, and reproducing apparatus
EP1408114B1 (en) 2002-10-11 2007-01-03 Imvision GmbH Modular antigen-transporter-molecules (MAT-molecules) for modulating immune responses, corresponding constructs and methods and uses thereof
DK1440979T3 (en) * 2003-01-21 2005-12-19 Biomay Prod & Handel Process for the preparation of hypoallergenic mosaic proteins
ATE384741T1 (en) 2003-04-24 2008-02-15 Imvision Gmbh RECOMBINANT FEL D 1 ALLERGEN
DE602004026048D1 (en) 2003-05-07 2010-04-29 Chemo Sero Therapeut Res Inst PROCESS FOR CLEANING THE MODIFIED MAINSTALENER OF MILBEN
DE10359351A1 (en) 2003-12-16 2005-07-21 Merck Patent Gmbh DNA sequence and recombinant production of group-4 major allergens from cereals
WO2007065633A1 (en) * 2005-12-05 2007-06-14 Imvision Ag Modulation of the immune response by administration of intralymphatic transduction allergen (itag) -molecules
US9340580B2 (en) 2007-08-15 2016-05-17 Circassia Limited Peptide with multiple epitopes
UY31930A (en) * 2008-06-25 2010-01-29 Boheringer Ingelheim Pharma Kg RECOMBINANT DAMAGED PESTIVIRUS, IN PARTICULAR TO CSFV, BVDV OR RECOMBINANT DAMPED BDV
JP2011212008A (en) * 2010-03-16 2011-10-27 Olympus Corp FLUORESCENT PROTEIN AND METHOD FOR MEASURING pH
JPWO2012121395A1 (en) 2011-03-09 2014-07-17 国立大学法人徳島大学 Cholesterol-dependent cytolytic toxin variants and their use in DDS
US9546200B2 (en) 2011-06-09 2017-01-17 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Peptide for protection of allergic respiratory disorders
KR20160138283A (en) 2014-03-31 2016-12-02 베링거잉겔하임베트메디카게엠베하 Improved modular antigen transportation molecules and uses therof
MX2018003850A (en) 2015-09-30 2018-06-15 Boehringer Ingelheim Vetmedica Gmbh Improved modular antigen transportation molecules and uses therof in animals.
CN107389010A (en) * 2017-07-25 2017-11-24 爱佩仪中测（成都）精密仪器有限公司 Improve the supporting mechanism of three-dimensional measurement instrument measurement accuracy

Also Published As

Publication number Publication date
EA201691981A1 (en) 2017-03-31
US9920101B2 (en) 2018-03-20
AU2015239770B2 (en) 2020-07-02
US10919945B2 (en) 2021-02-16
JP6370398B2 (en) 2018-08-08
AU2015239770A1 (en) 2016-08-04
CA2943690A1 (en) 2015-10-08
US20150274790A1 (en) 2015-10-01
KR20160138283A (en) 2016-12-02
TWI705823B (en) 2020-10-01
EP3125933B1 (en) 2022-05-18
EA034692B1 (en) 2020-03-06
WO2015150243A1 (en) 2015-10-08
CN106132996B (en) 2020-10-09
TW201607554A (en) 2016-03-01
JP2017510268A (en) 2017-04-13
EP3125933A1 (en) 2017-02-08
CN106132996A (en) 2016-11-16
MX2016012840A (en) 2017-05-09
US20180170978A1 (en) 2018-06-21

Similar Documents

Publication Publication Date Title
AR100310A1 (en) MOLECULES FOR TRANSPORTATION OF IMPROVED MODULAR ANTIGEN AND ITS USES
CO2018012374A2 (en) Antibody molecules for cancer treatment
CY1122800T1 (en) COMPOSITIONS OF FACTOR VIII AND METHODS OF MAKING AND USING THEM
CY1120103T1 (en) LENGTH CARE PRODUCER SCALE SYSTEM COMPATIBLE WITH INDUSTRIAL PHARMACEUTICAL APPLICATIONS
MX2020006065A (en) Methods and products for nucleic acid production and delivery.
CA3062698A1 (en) Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof
MY176332A (en) Multispecific antibody constructs
MX2017008817A (en) Compositions and methods for protein glycosylation.
BR112016016658A2 (en) fusion protein of an antibody, polynucleotide, vector, host cell, pharmaceutical composition, methods for producing a fusion protein and treating a disease in an individual and use of the fusion protein
MX2021010668A (en) Cytokine fusion proteins.
BR112019004711A2 (en) chimeric antigen receptors comprising bcma specific type III fibronectin domains and uses thereof
MX2018003850A (en) Improved modular antigen transportation molecules and uses therof in animals.
EA201501080A1 (en) NEW APPLICATIONS OF POSSIBLE ABILITIES TO PUNCH THE PEPTIDE INHIBITORS IN THE CELL OF JNK SIGNAL TRANSFORMATION TREATMENT FOR THE TREATMENT OF VARIOUS DISEASES
AR105822A1 (en) INSULIN ANALOGS
AU2017260426A1 (en) Engineered nucleases useful for treatment of hemophilia A
AR100606A1 (en) VARIANTS OF LIPASES AND POLINUCLEOTIDES CODING THEM
MX2014015667A (en) Use of polypeptides having protease activity in animal feed and detergents.
MX2015010078A (en) Use of polypeptides having protease activity in animal feed.
CO2017011431A2 (en) Variant epidermal growth factor receptor fusion proteins iii - mesothelin
EA201691011A1 (en) SEQUENCE OF MODIFIED ENDOLYSINE EL188
EA201691004A1 (en) SEQUENCE OF MODIFIED ENDOLYSIN KZ144
BR112015019719A2 (en) ENHANCED TNF-BINDING PROTEINS
PE20230343A1 (en) PEPTIDES THAT STIMULATE ANTI-TUMORAL IMMUNE RESPONSES
AR102120A1 (en) MODIFIED INTERFER WITH REDUCED IMMUNOGENICITY
AR113488A1 (en) VARIANTS OF a-AMYLASE AND POLYNUCLEOTIDES THAT CODE THEM